首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2018年 6期药物性肝损伤 => 述评 =>药物性肝损伤的研究进展及我国存在的问题
药物性肝损伤的研究进展及我国存在的问题
Research advances in drug-induced liver injury and existing problems in China
文章发布日期:2018年05月07日  来源:  作者:陈成伟  点击次数:689次  下载次数:198次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:目前,药物性肝损伤(DILI)已成为临床最常见急性肝损伤的原因。从DILI的发病机制、新的生物标志物、肝脏对药物毒性的耐受、适应与易感性、ALT诊断阈值等方面进行了阐述,提醒应了解诊断量表发展史,以统一标准和认识,要重视草药和膳食补充剂引起的DILI,并深入研究其导致DILI的发病机制,从而预防或减少DILI的发生。我国DILI研究存在的问题和差距是明显的,基础研究相当匮乏,在临床方面也有很多空白,因此,我们要努力跟上国际研究的步伐,使药物更好地为人类服务。
【Abstract】:At present, Drug-induced liver injury(DILI) has become the most common cause of acute liver injury in clinical practice. This article elaborates on the pathogenesis of DILI, new biomarkers, liver tolerance to drug toxicity, adaptability and susceptibility, and testing threshold of alanine aminotransferase. Meanwhile, we should understand the development history of diagnostic scale, develop unified standards and understanding, and attach importance to DILI induced by medicinal herbs and dietary supplements, and in-depth studies on the pathogenesis of DILI should be performed to prevent or reduce DILI. There are several problems in DILI studies in China and obvious gaps between China and foreign countries, with a lack of basic research and blanks in clinical aspects. Therefore, we must strive to keep up with international research so that drugs can better serve the human.
【关键字】:药物性肝损伤; 述评
【Key words】:drug-induced liver injury; editorial
【引证本文】:
CHEN CW. Research advances in drug-induced liver injury and existing problems in China[J]. J Clin Hepatol, 2018, 34(6): 1147-1151. (in Chinese) 陈成伟. 药物性肝损伤的研究进展及我国存在的问题[J]. 临床肝胆病杂志, 2018, 34(6): 1147-1151.

相关文章
地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号